A Randomized Open-label Four-way Crossover Study to Compare the PK, Safety, and Tolerability of M207 3.8 mg (Administered as Two 1.9 mg Patches) at Two Different Application Locations (Upper Arm and Thigh) for 30 Minutes With Intranasal Zolmitriptan 2.5 mg and 1 Hour Wear Time (Upper Arm) in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2019
At a glance
- Drugs Zolmitriptan (Primary) ; Zolmitriptan
- Indications Migraine
- Focus Pharmacokinetics
- Sponsors Zosano Pharma
- 30 Jan 2019 Status changed from active, no longer recruiting to completed.
- 27 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Nov 2018 Status changed from not yet recruiting to recruiting.